Prelude Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Prelude Therapeutics Incorporated

15/03/2023 13:00

* Prelude Therapeutics Inc  PRLD.OQ  reported a quarterly
adjusted
loss of 60 cents​​ per share for the quarter ended in December.
The mean expectation of five analysts for the quarter was for a
loss of 63 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Prelude Therapeutics Inc's reported EPS for the quarter
was a
loss of 60 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Prelude Therapeutics Inc shares had fallen by 0.5% this
quarter.
    * The company reported a quarterly loss of $28.64 million.
    * Wall Street's median 12-month price target for Prelude
Therapeutics Inc is $10.00 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 15 at 01:00 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.63          -0.60          Beat
 Sep. 30 2022      -0.64          -0.63          Beat
 Jun. 30 2022      -0.61          -0.58          Beat
 Mar. 31 2022      -0.65          -0.63          Beat